Juan Camilo Arjona Ferreira Net Worth

The estimated Net Worth of Ferreira Juan Camilo Arjona is at least $10.2 Milion dollars as of 18 January 2023. Juan Arjona owns over 1,109 units of Myovant Sciences Ltd stock worth over $6,655,534 and over the last 7 years he sold MYOV stock worth over $1,592,746. In addition, he makes $1,978,590 as Chief Commercial Officer - Myovant Sciences a Inc at Myovant Sciences Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Juan Ferreira MYOV stock SEC Form 4 insiders trading

Juan has made over 35 trades of the Myovant Sciences Ltd stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,109 units of MYOV stock worth $29,821 on 18 January 2023.

The largest trade he's ever made was selling 22,978 units of Myovant Sciences Ltd stock on 27 August 2021 worth over $549,864. On average, Juan trades about 4,236 units every 33 days since 2017. As of 18 January 2023 he still owns at least 246,684 units of Myovant Sciences Ltd stock.

You can see the complete history of Juan Arjona stock trades at the bottom of the page.

Juan Camilo Arjona Ferreira biography

Dr. Juan Camilo Arjona Ferreira M.D. serves as Chief Commercial Officer - Myovant Sciences, Inc of the Company. Dr. Arjona Ferreira has served as Chief Medical Officer of Myovant Sciences, Inc. since July 2017. From March 2014 to July 2017, Dr. Arjona Ferreira was Senior Vice President, Clinical Development at Shionogi Inc., a pharmaceutical company, where he served on its U.S. Senior Leadership Team and the Global Scientific Committee and was responsible for leading its U.S. Clinical Development organization. From July 2002 to March 2014, Dr. Arjona Ferreira worked at Merck & Co., Inc., a pharmaceutical company, where he held positions of increased responsibility, the last being Executive Director of Clinical Research in Women’s Health and led the product development teams for all programs in contraception and women’s health. He received his M.D. and completed his postgraduate specialist training in Obstetrics and Gynecology at Colegio Mayor del Rosario in Bogota, Colombia.

What is the salary of Juan Ferreira?

As the Chief Commercial Officer - Myovant Sciences a Inc of Myovant Sciences Ltd, the total compensation of Juan Ferreira at Myovant Sciences Ltd is $1,978,590. There are 3 executives at Myovant Sciences Ltd getting paid more, with Lynn Seely having the highest compensation of $6,222,670.

How old is Juan Ferreira?

Juan Ferreira is 50, he's been the Chief Commercial Officer - Myovant Sciences a Inc of Myovant Sciences Ltd since 2017. There are 11 older and 2 younger executives at Myovant Sciences Ltd. The oldest executive at Myovant Sciences Ltd is Kathleen Sebelius, 72, who is the Lead Independent Director.

What's Juan Ferreira's mailing address?

Ferreira's mailing address filed with the SEC is C/O MYOVANT SCIENCES, INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE, CA, 94005.

Insiders trading at Myovant Sciences Ltd

Over the last 8 years, insiders at Myovant Sciences Ltd have traded over $5,780,890 worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth $2,001,605,371 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... a Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $25,106,967. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth $1,393,178,400.

What does Myovant Sciences Ltd do?

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.

Complete history of Juan Arjona stock trades at Myovant Sciences Ltd

Myovant Sciences Ltd executives and stock owners

Myovant Sciences Ltd executives and other stock owners filed with the SEC include:

• Lynn Seely,
  Principal Executive Officer, Director
• Matthew Lang,
  General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
• Frank Karbe,
  Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.
• Juan Camilo Arjona Ferreira,
  Chief Commercial Officer - Myovant Sciences, Inc
• David C. Marek,
  CEO & Director
• Matthew Lang J.D.,
  Gen. Counsel & Corp. Sec.
• Kathleen Sebelius,
  Lead Independent Director
• Myrtle Potter,
  Chairman of the Board
• Mark Guinan,
  Independent Director
• Terrie Curran,
  Independent Director
• Adele Gulfo,
  Director, Interim Chief Commercial Officer
• Hiroshi Nomura,
  Director
• Dr. Andria Langenberg M.D.,
  Head of Drug Safety & Pharmacovigilance
• Dr. Teresa Perney Ph.D.,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Juan Camilo Arjona Ferreira M.D.,
  Chief Medical Officer
• Bryan Selby,
  Sr. VP of Product Devel.
• Julie Tran MBA, MSHR,
  Sr. VP of HR
• Albert Liao,
  Director of Corp. Communications
• Ryan Crowe,
  VP of Investor Relations
• Uneek Mehra,
  Chief Financial & Bus. Officer
• Kim Sablich,
  Chief Commercial Officer
• Uneek Mehra,
  Principal Financial Officer
• David C Marek,
  Principal Executive Officer
• Wayne S De Veydt,
  Director
• Mark Altmeyer,
  Director
• Pharmaceuticals Internation...,
  10% owner
• Global Investors Lp Viking ...,
  
• Holdings Ltd.Dexcel Pharma ...,
  
• Global Performance Llc Viki...,
  
• Investments (Uk) Ltd Soft B...,
  
• Sciences Ltd. Roivant,
  10% owner
• Patrick Machado,
  
• Associates Gp Llcqvt Fund V...,
  
• Global Performance Llc Viki...,
  
• Pharmaceuticals Internation...,
  
• Frank Torti,
  Director
• Chemical Co., Ltd.Sumitomo ...,
  
• Lauren Merendino,
  Chief Commercial Officer
• Nancy Valente,
  Director